Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
Four transactions above $10 billion and 38 acquisitions industrywide signal Big Pharma’s pivot from early bets to buying …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
Gene-edited cell therapy exagamglogene autotemcel extends to pediatric patients as young as two, based on trial data showing …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
GSK’s acquisition of Nuvalent, J&J’s deal for Firefly Bio, and a string of Eli Lilly acquisitions define a …
The acquisition, announced in March and targeting Centessa’s orexin receptor agonist programme, signals Lilly’s intention to build a …
The Alphabet-backed spinout of DeepMind’s AlphaFold programme has raised the largest private financing round in AI drug discovery …
Average deal value has climbed to $527 million per transaction, with large-cap pharma companies pursuing late-stage assets to …
Already a subscriber? Log in